3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
Patent 5714499 Issued on February 3, 1998. Estimated Expiration Date: 
February 3, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 3, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsApplicationNo. 261498 filed on 06/17/1994US Classes:514/316, Plural piperidine rings514/89, Hetero ring is six-membered and includes only one ring nitrogen514/222.5, Three or more ring hetero atoms in the six-membered hetero ring514/237.2, The additional hetero ring is attached indirectly to the morpholine ring by an acyclic chain having a hetero atom as a chain member514/237.8, Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding514/256, 1,3-diazines (e.g., pyrimidines, etc.)514/326, The additional ring is a hetero ring514/369, Chalcogen bonded directly to ring carbon of the thiazole ring514/425, Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding544/8, Thiadiazines544/129, Piperidine ring544/162, Nitrogen attached directed or indirectly to morpholine ring by nonionic bonding544/309, At 2-position and at 4- or 6-position544/310, Additional hetero ring which is unsaturated546/208, Ring nitrogen in the additional hetero ring546/209, Ring sulfur or ring oxygen in the additional hetero ring548/184, Nitrogen attached directly to the thiazole ring by nonionic bonding548/185, Having -C(=X)-, wherein X is chalcogen, bonded directly to nitrogen548/544And chalcogen bonded directly to a ring carbon of the five membered hetero ring which is not adjacent to the ring nitrogen (e.g., 2,4 pyrrolidinediones, etc.)ExaminersPrimary: Ivy, C. WarrenAssistant: Dahlen, Garth M. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/445C07D 401/12 AbstractThe present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.Other References
Field of SearchPlural piperidine ringsThree or more ring hetero atoms in the six-membered hetero ring The additional hetero ring is attached indirectly to the morpholine ring by an acyclic chain having a hetero atom as a chain member Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding 1,3-diazines (e.g., pyrimidines, etc.) The additional ring is a hetero ring Chalcogen bonded directly to ring carbon of the thiazole ring Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding Having -C(=X)-, wherein X is chalcogen, attached indirectly to a piperdine ring by nonionic bonding Ring nitrogen in the additional hetero ring Ring sulfur or ring oxygen in the additional hetero ring Thiadiazines Piperidine ring Nitrogen attached directed or indirectly to morpholine ring by nonionic bonding At 2-position and at 4- or 6-position Additional hetero ring which is unsaturated Nitrogen attached directly to the thiazole ring by nonionic bonding Having -C(=X)-, wherein X is chalcogen, bonded directly to nitrogen And chalcogen bonded directly to a ring carbon of the five membered hetero ring which is not adjacent to the ring nitrogen (e.g., 2,4 pyrrolidinediones, etc.) |
| ||||||||||||||
